Evidence-Based Strategies to Promote Long-Term Cardiac Implant Site Health: Review of the Literature

Leo Licari¹, Simona Viola², Claudia Carolla³, Sofia Campanella³, Giuseppe Salamone³

1. Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, ITA 2. Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, ITA 3. Surgical, Oncological and Oral Sciences, Policlinico Universitario P. Giaccone, University of Palermo, Palermo, ITA

Corresponding author: Leo Licari, lele.licari@gmail.com

Abstract

Cardiac implantable electronic devices (CIEDs) are commonly used nowadays. The association between CIED placement and infections is responsible for the high mortality and device explantation rate. Since CIED placement has increased in the past decade, CIED-related complications have risen. In order to reduce the CIED-related complications rate, the prevention of device infection represents the main goal. Over time, many different studies have proven the importance of the measures to prevent CIED-related infections. This review aims to collect the actual recommendations for CIED infection prevention, providing an overview of the main evidence-based strategies.

Categories: Cardiac/Thoracic/Vascular Surgery, Cardiology, Healthcare Technology

Keywords: cardiac implantable electronic device (cied), infection, prevention, microbiology, surgery

Introduction And Background

Since the development of advanced hardware, such as transvenous electrodes and downsized generators, the placement of cardiac implantable electronic devices (CIEDs) makes available surgical approaches that have been revealed to be easy to perform and safe. This evidence justifies the rapid rise of CIED procedures performed over the past two decades and the wide spectrum of clinical indications designed for its placement [1-8].

The implantation of CIEDs is not free of complications [9]. Infection represents the most critical complication, and it rates between 1% and 7% of device implantation [9]. Infection often requires device explantation; fatalities occur at a rate between 3% and 19% in patients with device infection. The majority of CIED infections are supported by staphylococcal species (60%-80%) such as *S. epidermidis* and *S. aureus*. The American Heart Association (AHA)/Heart Rhythm Society (HRS) recommends antibiotic prophylaxis for infection prevention [6,10-13].

This article aims to investigate the recent trends in surgical techniques for CIED implant site management in order to improve or enhance the long-term health of the implant site and device. The research conducted is a review of the literature.

Review

We conducted a systematic review. A systematic search was performed in MEDLINE, as well as in Scopus, PubMed Publisher, Google Scholar, and the Cochrane Library, with a search period until August 2020. Searches were adapted to each database and carried out using the specific controlled vocabulary of each database, if available, as well as free-text words.

Two reviewers (L.L. and G.S.) independently evaluated the identified records. All records were screened by title and abstract for eligibility, and the full text of the eligible records was assessed. The English language restriction of the articles was set. Data were assembled in a database set up in Microsoft Office Excel 2016 (Microsoft Corporation, Redmond, WA). The data presented in this review were directly abstracted from the original articles. No statistical analyses were performed.

Surgical site infections (SSIs) are defined by the Centers for Disease Control and Prevention (CDC) as an infection that occurs in the part of the body where the surgery took place and includes superficial, deep, and organ space SSIs [14]. Prevention of SSIs is focused upon three moments in the surgical operation that the World Health Organization (WHO) summarizes in pre, intra, and postoperative measures [15].

Preoperative measures

Patients with fever for 24 hours before implantation are at high risk of CIED infection, and the device

Review began 10/26/2020

Review ended 01/29/2021

Published 01/31/2021

© Copyright 2021

Licari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Licari L, Viola S, Carolla C, et al. (January 31, 2021) Evidence-Based Strategies to Promote Long-Term Cardiac Implant Site Health: Review of the Literature. Cureus 13(1): e13027. DOI 10.7759/cureus.13027

placement is recommended to be postponed [16]. Every sign of infection should be screened before CIED implantation and if the infection is confirmed, it should be adequately treated prior to performing the operation [17].

The CDC recommends not to shave the skin perioperatively because it is related to a higher risk of SSIs. Therefore, the CDC recommends cutting the body hair around the incision area only if they interfere with the operation [14].

A preoperative shower or bath with an antiseptic agent is strictly recommended, and it should be done the night before surgery [14]. Finally, antiseptic skin preparation prior to surgery is mandatory for SSI prevention [14].

Even though cardiovascular surgery is a clean surgery, the risk of postoperative SSIs is still present and relatively low. The occurrence of SSI could represent a life-threatening condition. Therefore, systemic prophylactic preoperative antibiotics are routinely used. At present, there are not still guidelines about their use in CIED implantation, but different studies report an advantage in their use [16,18-20]. First-generation cephalosporins, such as cefazolin 2 g, is effective for prophylaxis. It should be administered intravenously (IV) at least 60 minutes before the procedure. If penicillin allergy is known, clindamycin 600 mg IV or vancomycin 1 g IV should be administered 60 minutes prior to the procedure [21].

Finally, the CDC strictly recommends abstaining from smoking for at least one month prior to elective surgery and adequately controlling serum blood glucose levels in diabetic patients. Other host factors associated with a greater risk of CIED infection are often unmodifiable and are represented by comorbidities or drug intake [16]. The risk of infection is also related to the type of device implanted.

Intraoperative measures

The role of the preoperative surgical scrub is well-established [22]. Protocols require that physicians perform surgical scrub, including the hands and the forearms, for at least five minutes with antimicrobial soap or an alcohol-based hand rub. Physicians must therefore dress in a sterile gown and gloves for the duration of the surgical procedure.

The surgical technique must be rigorous and must give attention to sterility throughout the operation. CIEDs are implanted in pockets fashioned in the pre-pectoral subcutaneous space, avoiding fascia incision. Traumatic injury to the small vessels and nerve system can cause accidental bleeding, postoperative pain, and hematoma formation. The dissection of the subcutaneous space must be carefully performed looking for adequate hemostasis. Hematoma must be avoided because it represents a major risk factor for SSI. Irrigation of the pocket prior to definitive suture helps reveal causes of bleeding. It also determines the mechanical debris removal and dilution of contaminants. The effectiveness of prophylactic intrapocket antibiotics in CIEDs has not been proved. The use of monofilament resorbable sutures for closure of the pocket is recommended. The administration of hemostatic agents in the surgical pocket improves postoperative healing reducing the hematoma formation rate. The use of closed incision negative pressure systems (ciNPTs) helps prevent SSIs and CIEDs removal [23].

Postoperative measures

The wound must be maintained clean and dry. If a hematoma occurs, it should be treated conservatively. Hematoma must be evacuated if it increases the skin tension, determining the risk of wound dehiscence. The evacuation of the hematoma must be performed in sterile conditions avoiding contamination of the CIED. The evidence shows that the routine administration of postoperative antibiotics is not useful and the American Heart Association (AHA) guidelines [24] do not recommend their routine use. Postoperative antibiotics should be used only if signs of SSI are present, and they should be administered on culture specimen examination and antibiogram.

Infection of cardiac devices remains a serious problem despite improvements in implantation techniques. Recently, Uslan et al. demonstrated that the estimated CIED infection rate is about 1.9 per 1,000 device-years implanted [10]. The importance of species characterization in SSIs was proven elsewhere [25-33]. The main species identified is the Staphylococcal that accounts for more than 66% of CIED infections. Coagulase-negative Staphylococcus species are a common cause of microbiological specimen contamination. One of the most important virulence factors for some of these pathogens is biofilm formation. The remaining 33% of CIED infections are caused by Gram-negative bacilli and Candida species [34].

The mechanism commonly described for CIED infection is represented by the contamination of the pocket at the time of device implantation, or postoperatively, following a cutaneous infection or the contamination of the device itself or its leads. The infection can spread along the electrode to the endocardium. Another mechanism of infection is the hematogenous seeding of the electrode during bacteremia from a focal infection located elsewhere in the body. Recent studies reported that the estimated endocarditis rate developing by the pocket infection is about 25% of the CIED infections [35].

The signs of CIED infection are represented by an inflammatory reaction or cutaneous erosion. The local signs of infection are often accompanied by pain and fever. Local signs of infection include erythema, fluctuance, wound dehiscence, tenderness, and purulent spillage [34].

When a CIED infection occurs, its management is based on specific antibiotic therapy administration and, eventually, complete removal of the device. Removal of an infected CIED can be performed either by percutaneous lead traction through the generator pocket or by a surgical approach [34]. The use of advanced medications, such as ciNPT and vacuum-assisted closure (VAC) therapy, can be considered to improve healing [23].

The identification of the risk factors for CIED complications is part of the prevention. Risk factors can be divided into patient-related and procedure/device-related. Among the first, gender, age, and comorbidities are recognized as major risk factors. The use of certain medications related to the comorbidities are recognized as risk factors too. Among the second, the lack of rigorous asepsis protocols adoption and postoperative surgical site occurrences (SSOs) are recognized as major risk factors.

Conclusions

SSI is a serious postoperative complication of CIED implantation that could require device explantation and delay the treatment of cardiac rhythm disease. It sometimes results in death. The best SSI control is its prevention. The most important factors in SSI prevention are rigorous operative technique, antibiotic prophylaxis, and the use of advanced medications such as ciNPTs.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Camunas J, Mehta D, Ip J, Gomes JA: Total pectoral implantation: a new technique for implantation of transvenous defibrillator lead systems and implantable cardioverter-defibrillator. *Pacing Clin Electrophysiol.* 1993, 16:1380-1385. [10.1111/j.1540-8159.1993.tb01732.x](#)
2. Fitzpatrick AP, Lesh MD, Epstein LM, et al.: Electrophysiological laboratory, electrophysiologist-implanted nonthoracotomy-implantable cardioverter/defibrillators. *Circulation.* 1994, 89:2503-2508. [10.1161/01.CIR.89.6.2503](#)
3. Stanton MS, Hayes DL, Munger DM, et al.: Consistent subcutaneous prepectoral implantation of a new implantable cardioverter-defibrillator. *Mayo Clin Proc.* 1994, 69:309-314. [10.1016/S0025-6196\(12\)62213-7](#)
4. Zipes DP: The implantable cardioverter-defibrillator revolution continues. *Mayo Clin Proc.* 1994, 69:395-396. [10.1016/S0025-6196\(12\)62229-0](#)
5. Tung RT, Bajaj AK: Safety of implantation of a cardioverter-defibrillator without general anesthesia in an electrophysiology laboratory. *Am J Cardiol.* 1995, 75:908-912. [10.1016/S0002-9149\(99\)80685-7](#)
6. Epstein AE, DiMarco JP, Ellenbogen KA, et al.: ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities.: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *Circulation.* 2008, 117:350. [10.1161/CIRCULATIONAHA.108.189742](#)
7. Hunt SA, Abraham WT, Chin MH, et al.: 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation.* 2009, 119:391-479. [10.1161/CIRCULATIONAHA.109.192065](#)
8. Lai KK, Fontecchio SA: Infections associated with implantable cardioverter- defibrillators placed transvenously and via thoracotomies: epidemiology, infection control and management. *Clin Infect Dis.* 1998, 27:265-269. [10.1086/514673](#)
9. Cacoub P, Leprince P, Nataf P, et al.: Pacemaker infective endocarditis. *Am J Cardiol.* 1998, 82:480-485. [10.1016/S0002-9149\(98\)00365-8](#)
10. Uslan DZ, Sohail St MR, Sauver JL, et al.: Permanent pacemaker and implantable cardioverter-defibrillator infection. A population-based study. *Arch Intern Med.* 2007, 167:669-675. [10.1001/archinte.167.7.669](#)
11. Chua JD, Wilkoff BL, Lee I, Juratli N, Longworth DL, Gordon SM: Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. *Ann Intern Med.* 2000, 133:604-608. [10.7326/0003-4819-133-8-200010170-00011](#)
12. Sohail MR, Uslan DZ, Khan AH, et al.: Management and outcome of permanent and implantable cardioverter-defibrillator infections. *J Am Coll Cardiol.* 2007, 49:1851-1859. [10.1016/j.jacc.2007.01.072](#)
13. Kloos WE, Bannermann TL: Update on the clinical significance of coagulase-negative staphylococci. *Clin*

- Microbiol Rev. 1994, 7:1451-1459. [10.1128/CMR.7.1.117](#)
14. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, The Hospital Infection Control Practices Advisory Committee: Guideline for prevention of surgical site infection, 1999. *Am J Infect Control*. 1999, 27:97-132. [10.1086/501620](#)
 15. Leaper DJ, Edmiston CE: World Health Organization: global guidelines for the prevention of surgical site infection. *J Hosp Infect*. 2017, 95:135-136. [10.1016/j.jhin.2016.12.016](#)
 16. Klug D, Balde M, Pavin D, et al.: Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators. Results of a large prospective study. *Circulation*. 2007, 116:1349-1355. [10.1161/CIRCULATIONAHA.106.678664](#)
 17. Katsuhiko I: Perioperative management for the prevention of bacterial infection in cardiac implantable electronic device placement. *J Arrhythm*. 2015, 32:283-286. [10.1016/j.joa.2015.06.007](#)
 18. Sohail MR, Uslan DZ, Khan AH, et al.: Risk factor analysis of permanent pacemaker infection. *Clin Infect Dis*. 2007, 45:166-173. [10.1086/518889](#)
 19. Da Costa A, Kirkorian G, Cucherat M, et al.: Antibiotic prophylaxis for permanent pacemaker implantation. A meta-analysis. *Circulation*. 1998, 97:1796-1801. [10.1161/01.CIR.97.18.1796](#)
 20. de Oliveira JC, Martinelli M, Nishioka SA, et al.: Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators. Results of a large, prospective, randomized, double-blinded, placebo-controlled trial. *Circ Arrhythm Electrophysiol*. 2009, 2:29-34. [10.1161/CIRCEP.108.795906](#)
 21. Crader MF, Varacallo M: Preoperative Antibiotic Prophylaxis. StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2020.
 22. Boyce JM, Pittet D: Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. *Infect Control Hosp Epidemiol*. 2002, 23:3-40. [10.1067/mic.2002.130391](#)
 23. Licari L, Campanella S, Carolla C, Viola S, Salamone G: Closed incision negative pressure therapy achieves better outcome than standard wound care: clinical outcome and cost-effectiveness analysis in open ventral hernia repair with synthetic mesh positioning. *Cureus*. 2020, 12:e8283. [10.7759/cureus.8283](#)
 24. Baddour LM, Epstein AE, Erickson CC, et al.: Update on cardiovascular implantable electronic device infections and their management. A scientific statement from the American Heart Association. *Circulation*. 2010, 121:458-477. [10.1161/CIRCULATIONAHA.109.192665](#)
 25. Salamone G, Licari L, Agrusa A, et al.: Usefulness of ileostomy defunctioning stoma after anterior resection of rectum on prevention of anastomotic leakage. A retrospective analysis. *Ann Ital Chir*. 2016, 87:155-160.
 26. Salamone G, Falco N, Atzeni J, Tutino R, Licari L, Gulotta G: Colonic stenting in acutely obstructed left-sided colon cancer clinical evaluation and cost analysis. *Ann Ital Chir*. 2014, 85:556-562.
 27. Salamone G, Tutino R, Atzeni J, Licari L, Falco N, Orlando G, Gulotta G: Liver hydatidosis: Reasoned indications of surgical treatment. Comparison between conservative and radical techniques. Retrospective study. *Ann Ital Chir*. 2014, 85:422-430.
 28. Salamone G, Licari L, Randisi B, et al.: A primary subcutaneous hydatid cyst in the thigh. A case report. *Ann Ital Chir*. 2016, 87:1-5.
 29. The 2017 European Society of Coloproctology (ESCP) collaborating group: An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesorectal excision (TaTME). *Colorectal Dis*. 2018, 20:33-46. [10.1111/codi.14376](#)
 30. Porrello C, Gullo R, Vaglica A, et al.: Pulmonary laser metastasectomy by 1318-nm neodymium-doped yttrium-aluminum garnet laser: a retrospective study about laser metastasectomy of the lung. *Surg Innov*. 2018, 25:142-148. [10.1177/1553350617752263](#)
 31. Cocorullo G, Tutino R, Falco N, Salamone G, Fontana T, Licari L, Gulotta G: Laparoscopic ileocecal resection in acute and chronic presentations of Crohn's disease. A single center experience. *G Chir*. 2017, 37:220-223.
 32. Salamone G, Licari L, Guercio G, et al.: The abdominal wall hernia in cirrhotic patients: a historical challenge. *World J Emerg Surg*. 2018, 13:35. [10.1186/s13017-018-0196-z](#)
 33. Salamone G, Licari L, Atzeni J, Tutino R, Gulotta G: Histologic considerations about a rare case of recurrent incisional hernia on McBurney incision. *Ann Ital Chir*. 2014, [Epub]:
 34. Koutentakis M, Siminelakis S, Korantzopoulos P, et al.: Surgical management of cardiac implantable electronic device infections. *J Thorac Dis*. 2014, 6:173-179. [10.3978/j.issn.2072-1439.2013.10.23](#)
 35. Villamil Cajoto IV, Rodríguez Framil M, Van den Eynde Collado A, Villacián Vicedo MJ, Canedo Romero C: Permanent transvenous pacemaker infections: an analysis of 59 cases. *Eur J Intern Med*. 2007, 18:484-488. [10.1016/j.ejim.2007.02.015](#)